Kalpit Patel
Stock Analyst at B. Riley Securities
(1.37)
# 3,197
Out of 4,748 analysts
50
Total ratings
30.56%
Success rate
-8.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kalpit Patel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BCYC Bicycle Therapeutics | Maintains: Neutral | $28 → $17 | $12.98 | +30.97% | 6 | Dec 13, 2024 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $27 → $20 | $22.49 | -11.07% | 5 | Dec 10, 2024 | |
| PDSB PDS Biotechnology | Maintains: Buy | $9 → $7 | $1.52 | +360.53% | 5 | Nov 25, 2024 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $85 → $40 | $9.62 | +315.80% | 2 | Sep 20, 2024 | |
| VSTM Verastem | Maintains: Buy | $21 → $7 | $6.03 | +16.09% | 3 | Jul 24, 2024 | |
| KYMR Kymera Therapeutics | Maintains: Neutral | $31 → $36 | $39.40 | -8.63% | 2 | Jul 9, 2024 | |
| OVID Ovid Therapeutics | Maintains: Buy | $9 → $3 | $0.74 | +304.64% | 2 | Jun 18, 2024 | |
| VRDN Viridian Therapeutics | Downgrades: Neutral | $25 → $20 | $19.43 | +2.93% | 3 | May 9, 2024 | |
| XFOR X4 Pharmaceuticals | Downgrades: Neutral | $3 → $1 | $0.74 | +36.02% | 1 | Dec 12, 2023 | |
| DERM Journey Medical | Reiterates: Buy | $6 | $3.94 | +52.28% | 5 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $36 | $14.24 | +152.81% | 2 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $2.89 | +73.01% | 2 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $9 → $3 | $0.27 | +1,020.24% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $18 | $1.84 | +878.26% | 2 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $2.38 | +110.08% | 2 | Jul 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $6 | $1.56 | +284.62% | 2 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $10 | $6.60 | +51.52% | 1 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 | $14.65 | +411.95% | 2 | Sep 3, 2021 |
Bicycle Therapeutics
Dec 13, 2024
Maintains: Neutral
Price Target: $28 → $17
Current: $12.98
Upside: +30.97%
Rigel Pharmaceuticals
Dec 10, 2024
Maintains: Neutral
Price Target: $27 → $20
Current: $22.49
Upside: -11.07%
PDS Biotechnology
Nov 25, 2024
Maintains: Buy
Price Target: $9 → $7
Current: $1.52
Upside: +360.53%
Corbus Pharmaceuticals Holdings
Sep 20, 2024
Maintains: Buy
Price Target: $85 → $40
Current: $9.62
Upside: +315.80%
Verastem
Jul 24, 2024
Maintains: Buy
Price Target: $21 → $7
Current: $6.03
Upside: +16.09%
Kymera Therapeutics
Jul 9, 2024
Maintains: Neutral
Price Target: $31 → $36
Current: $39.40
Upside: -8.63%
Ovid Therapeutics
Jun 18, 2024
Maintains: Buy
Price Target: $9 → $3
Current: $0.74
Upside: +304.64%
Viridian Therapeutics
May 9, 2024
Downgrades: Neutral
Price Target: $25 → $20
Current: $19.43
Upside: +2.93%
X4 Pharmaceuticals
Dec 12, 2023
Downgrades: Neutral
Price Target: $3 → $1
Current: $0.74
Upside: +36.02%
Journey Medical
Sep 7, 2023
Reiterates: Buy
Price Target: $6
Current: $3.94
Upside: +52.28%
Jul 25, 2023
Maintains: Buy
Price Target: $34 → $36
Current: $14.24
Upside: +152.81%
Mar 20, 2023
Reiterates: Buy
Price Target: $5
Current: $2.89
Upside: +73.01%
Nov 11, 2022
Downgrades: Neutral
Price Target: $9 → $3
Current: $0.27
Upside: +1,020.24%
Sep 22, 2022
Maintains: Buy
Price Target: $21 → $18
Current: $1.84
Upside: +878.26%
Jul 19, 2022
Maintains: Buy
Price Target: $6 → $5
Current: $2.38
Upside: +110.08%
Jun 7, 2022
Maintains: Buy
Price Target: $12 → $6
Current: $1.56
Upside: +284.62%
Jan 24, 2022
Maintains: Buy
Price Target: $24 → $10
Current: $6.60
Upside: +51.52%
Sep 3, 2021
Downgrades: Neutral
Price Target: $75
Current: $14.65
Upside: +411.95%